Download App

Log in to access Online Inquiry
Company Overview More
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
CEO: Harris Ph.D., Todd
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

TYRA TYRA BIOSCIENCES, INC.

7.9700.0000.00%
Close 05/25 00:00 ET
High
0.000
Open
0.000
Turnover
0
Low
0.000
Pre Close
7.970
Volume
0
Market Cap
332.84M
P/E(TTM)
Loss
52wk High
31.360
Shares
41.76M
P/E(Static)
Loss
52wk Low
6.250
Float Cap
87.28M
Bid/Ask %
0.00%
Historical High
31.360
Shs Float
10.95M
Volume Ratio
0.00
Historical Low
6.250
Dividend TTM
--
Div Yield TTM
--
P/B
1.14
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.00%
Amplitude
0.00%
Avg Price
0.000
Lot Size
1
Float Cap
87.28M
Bid/Ask %
0.00%
Historical High
31.360
Shs Float
10.95M
Volume Ratio
0.00
Historical Low
6.250
Dividend TTM
--
P/B
1.14
Dividend LFY
--
Turnover Ratio
0.00%
Amplitude
0.00%
Avg Price
0.000
Lot Size
1
Price Forecast

No Data

News

Comment

No More